To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions

Sandoz

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA); Drug: Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00881179

B013721

Details and patient eligibility

About

To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.

Enrollment: 24 patients

Sex: All

Ages: 18 to 59 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion criteria

• Positive test results for HIV or hepatitis B or C.
• Treatment for drug or alcohol dependence.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

24 participants in 2 patient groups

1

Experimental group

Description:

Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)

Treatment:

Drug: Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)

2

Active Comparator group

Description:

Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)

Treatment:

Drug: Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)